THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

Novo Nordisk has been on the hunt for differentiated ... a drug discovered and developed by Lexicon Pharmaceuticals, the companies announced Friday. LX9851 is an oral small molecule that blocks ...

Shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) climbed ~95% in the premarket trading on Friday after the Texas-based biotech announced an exclusive license agreement with Novo Nordisk (NVO ...

Novo Nordisk is expanding its obesity drug pipeline through a major licensing agreement with Lexicon Pharmaceuticals, acquiring the global rights to LX9851, a first-in-class oral therapy targeting ...

Lexicon Pharmaceuticals secured a licensing deal with Novo Nordisk for LX9851, with potential payments totaling $1 billion-plus royalties. Preclinical data show that LX9851 enhances weight loss ...

THE WOODLANDS, Texas, March 28, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has entered into an exclusive license agreement with Novo Nordisk A/S ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy LX9851.

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to LX9851, an experimental oral treatment for obesity and related metabolic disorders.